Emerging Hypervirulent Marek’s Disease Virus Variants Significantly Overcome Protection Conferred by Commercial Vaccines
Author:
Liu Jin-Ling12, Teng Man12ORCID, Zheng Lu-Ping12, Zhu Feng-Xia3, Ma Shu-Xue4, Li Lin-Yan125, Zhang Zhi-Hui12, Chai Shu-Jun12, Yao Yongxiu6ORCID, Luo Jun125ORCID
Affiliation:
1. Key Laboratory of Animal Immunology, Ministry of Agriculture and Rural Affairs of China & Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou 450002, China 2. UK-China Centre of Excellence for Research on Avian Diseases, Henan Academy of Agricultural Sciences, Zhengzhou 450002, China 3. Zhumadian Center for Animal Disease Control and Prevention, Zhumadian 463000, China 4. Suiping Center for Animal Disease Control and Prevention, Zhumadian 463100, China 5. College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471003, China 6. The Pirbright Institute & UK-China Centre of Excellence for Research on Avian Diseases, Pirbright, Ash Road, Guildford GU24 0NF, Surrey, UK
Abstract
As one of the most important avian immunosuppressive and neoplastic diseases, Marek’s disease (MD), caused by oncogenic Marek’s disease virus (MDV), has caused huge economic losses worldwide over the past five decades. In recent years, MD outbreaks have occurred frequently in MD-vaccinated chicken flocks, but the key pathogenic determinants and influencing factors remain unclear. Herein, we analyzed the pathogenicity of seven newly isolated MDV strains from tumor-bearing chickens in China and found that all of them were pathogenic to chicken hosts, among which four MDV isolates, SDCW01, HNXZ05, HNSQ05 and HNSQ01, were considered to be hypervirulent MDV (HV-MDV) strains. At 73 days of the virus infection experiment, the cumulative incidences of MD were 100%, 93.3%, 90% and 100%, with mortalities of 83.3%, 73.3%, 60% and 86.7%, respectively, for the four viruses. The gross occurrences of tumors were 50%, 33.3%, 30% and 63.3%, respectively, accompanied by significant hepatosplenomegaly and serious atrophy of the immune organs. Furthermore, the immune protection effects of four commercial MD vaccines against SDCW01, CVI988, HVT, CVI988+HVT, and 814 were explored. Unexpectedly, during the 67 days of post-virus challenge, the protection indices (PIs) of these four MD vaccines were only 46.2%, 38.5%, 50%, and 28%, respectively, and the birds that received the monovalent CVI988 or HVT still developed tumors with cumulative incidences of 7.7% and 11.5%, respectively. To our knowledge, this is the first demonstration of the simultaneous comparison of the immune protection efficacy of multiple commercial MD vaccines with different vaccine strains. Our study revealed that the HV-MDV variants circulating in China could significantly break through the immune protection of the classical MD vaccines currently widely used. For future work, there is an urgent need to develop novel, more effective MD vaccines for tackling the new challenge of emerging HV-MDV strains or variants for the sustainable control of MD.
Funder
National Natural Science Foundation of China Natural Science Foundation of Henan Province Independent Innovation Project of Henan Academy of Agricultural Sciences BBSRC Newton Fund Joint Centre Awards on “UK-China Centre of Excellence for Research on Avian Diseases”
Subject
Virology,Infectious Diseases
Reference41 articles.
1. Swayne, D.E., Boulianne, M., Logue, C.M., McDougald, L.R., Nair, V., and Suarez, D.L. (2020). Disease of Poultry, John Wiley & Sons. 2. Industry-wide surveillance of Marek’s disease virus on commercial poultry farms;Kennedy;Avian Dis.,2017 3. ICTV Virus Taxonomy Profile: Herpesviridae 2021;Gatherer;J. Gen. Virol.,2021 4. Latency and Tumorigenesis in Marek’s Disease;Nair;Avian Dis.,2013 5. Bertzbach, L.D., Conradie, A.M., You, Y., and Kaufer, B.B. (2020). Latest insights into Marek’s disease virus pathogenesis and tumorigenesis. Cancers, 12.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|